Recent Anti‐angiogenic Drug Discovery Efforts To Combat Cancer. Issue 23 (16th June 2021)

• Record Type: Journal Article
• Authors: Upadhyay, Neha; Tilekar, Kalpana; Safuan, Sabreena; Kumar, Alan P.; Stalin, Jimmy; Ruegg, Curzio; Ramaa C S,
• Is Part Of: ChemistrySelect. Volume 6:Issue 23(2021)
• Page Start: 5689
• Page End: 5700
• Publication Date: 2021-06-16
• Subjects: Angiogenesis -- CD146 -- Growth factors -- VEGFR-2.; Chemistry -- Periodicals; 540.5
• DOI: 10.1002/slct.202101792
• Languages: English
• ISSNs: 2365-6549

Abstract

Abstract: The process of angiogenesis promotes tumor growth and metastatic spreading and angiogenesis inhibition has therapeutic efficacy in many preclinical models. The discovery of pathways mediating tumor angiogenesis, in particular VEGFs and their receptors, paved the way to the development of anti‐angiogenic drugs to translate into clinic as anti‐cancer agents. However, dozens of anti‐angiogenic drugs have been approved and routinely used under clinical practice. However, with the compelling preclinical evidence demonstrating anti‐cancer activity, therapeutic benefits in patients remained modest. Recent progress in understanding the biology of tumor angiogenesis and their molecular mechanisms opened a new prospect for improving therapeutic strategies. An emergent approach to improve efficacy and avoid resistance is to hit multiple angiogenesis pathways and or administration in combination with other anticancer agents. In this review, we have highlighted some of the emerging aspects and discussed new antiangiogenic drug discovery in the past five years. Abstract : Angiogenesis is the fundamental process which promotes growth and metastasis of tumors; hence, an essential therapeutic target for the development of novel candidates to prevent malignancies. Avascular tumors release growth factors which reach to their receptors at neighbouring endothelial cells and activate different signaling cascades. This involves proteolytic degradation, EC proliferation, migration and tube formation leading to tumor vascularization. Targeting these growth factors or their receptors with small molecules would be a useful strategy for the development of anti‐angiogenic agents.